Professional Development

Why are most of the speakers at congresses – and the vast majority of industry leaders – men?

Understanding what the Dickens motivates people to consider undergoing an elective ophthalmic procedure will help you guide them to a conclusion that’s right for them

One of the legends of refractive surgery talks about his career, his successes and failures, and about the state of ophthalmology today.

How We Met: Keith Barton and Kuldev Singh

The Ophthalmologist is one year old. We promised to tell you ophthalmology’s most engaging stories, and we’ve traveled the world to do so.

Sitting Down With Jim Mazzo, Operating Partner at Versant Ventures.

Sitting Down With Dirk Sauer, Novartis’ Global Head, Development Franchise Ophthalmics.

Big data analytics is the most sophisticated method yet devised for “augmenting the human intellect”.

Valeant and Allergan continue to joust, Santen purchases MSD’s ophthalmology drug portfolio in selected markets, and Kala completes a US$22.5 million Series B financing round

Purchase of the ex-US rights for Fovista is costing Novartis US$200 million down and up to a cool US$1 billion in milestone payments